Spero Therapeutics, Inc.
SPROSpero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for rare diseases and multi-drug resistant bacterial infections.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
Profile
Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for rare diseases and multi-drug resistant bacterial infections. The company's primary value proposition centers on its lead candidate, tebipenem HBr, which is positioned to be the first oral carbapenem antibiotic for adult patients with complicated urinary tract infections. Spero operates through a partnership-heavy model, leveraging external collaborations to fund and commercialize its late-stage pipeline while exploring new clinical-stage portfolio opportunities.
Spero is a pioneer in the oral carbapenem space, holding a first-mover advantage with tebipenem HBr for cUTI, supported by a significant licensing agreement with GSK.
Questions, answered.
- What is Spero Therapeutics, Inc.'s market cap?
- Spero Therapeutics, Inc. (SPRO) has a market capitalization of $68.3M and trades on NASDAQ.
- Who are Spero Therapeutics, Inc.'s competitors?
- Spero Therapeutics, Inc.'s key competitors include Merck & Co., Acurx Pharmaceuticals, Inc. Common Stock, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Spero Therapeutics, Inc. partner with?
- Spero Therapeutics, Inc.'s notable partners include GSK, Meiji Seika Pharma Co. Ltd., Everest Medicines, and others.
- What subsidiaries does Spero Therapeutics, Inc. have?
- Spero Therapeutics, Inc.'s subsidiaries include New Pharma License Holdings Limited, Spero Potentiator, Inc..
- Where is Spero Therapeutics, Inc. headquartered?
- Spero Therapeutics, Inc. is headquartered in United States of America and employs approximately 46 people. It has been publicly traded since 2017.